Best deals to access real time data! |
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ and Amex.
Monthly Subscription
for only
|
|
CHART Trader
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type | ISIN |
|---|---|---|---|---|
| Nektar Therapeutics (MM) | NKTR | NASDAQ | Common Stock | US6402681083 |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.1 | -0.47% | 21.29 | 21.44 | 21.11 | 21.37 | 21.39 | 09:53:55 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 21.28 | 21.33 | 0.05 | 0.23% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 262 | 32,986 | $ 21.2339 | $ 700.42k | 961.61k | 11.41 - 24.88 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:53:55 | 100 | $21.29 | USD |
Nektar Therapeutics (MM) Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 3.33B | 156.33M | $ -153.52M | -1.10 | 0.00 | 88.71M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ 0.00 | 0.00% | 63.3k | 90.00% |
Nektar Therapeutics (MM) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 9/20/2017 | 07:24 | PR Newswire (US) | Nektar Therapeutics Announces Seven Abstracts Accepted for.. |
| 9/12/2017 | 09:00 | PR Newswire (US) | Nektar Therapeutics Initiates PROPEL Clinical Study to.. |
| 9/08/2017 | 18:09 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 9/06/2017 | 18:00 | PR Newswire (US) | Nektar Therapeutics Presents Clinical Data from Phase 3.. |
| 9/06/2017 | 09:15 | PR Newswire (US) | Nektar Therapeutics' President and CEO, Howard W. Robin, To.. |
| 8/30/2017 | 09:00 | PR Newswire (US) | Nektar Therapeutics to Present Clinical Data from Phase 3.. |
| 8/25/2017 | 16:42 | Edgar (US Regulatory) | Current Report Filing (8-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NKTR Price Data
| Period † | Open | High | Low | VWAP | Min Vol | Max Vol | Avg. Daily Vol [m] | Change | % |
|---|---|---|---|---|---|---|---|---|---|
| 1 Week | 21.65 | 22.89 | 21.11 | 21.9763 | 822k | 2M | 1M | -0.36 | -1.66% |
| 1 Month | 18.47 | 22.89 | 18.19 | 21.2904 | 531k | 2M | 1M | 2.82 | 15.27% |
| 3 Months | 19.52 | 23.8 | 17.51 | 20.7208 | 364k | 3M | 1M | 1.77 | 9.07% |
| 6 Months | 22.86 | 24.88 | 17.33 | 20.1867 | 364k | 4M | 1M | -1.57 | -6.87% |
| 1 Year | 19.29 | 24.88 | 11.41 | 17.3694 | 241k | 15M | 2M | 2 | 10.37% |
| 3 Years | 12.94 | 24.88 | 9.16 | 14.9111 | 0 | 15M | 1M | 8.35 | 64.53% |
| 5 Years | 10.6 | 24.88 | 5.65 | 13.5443 | 0 | 15M | 1M | 10.69 | 100.85% |
Nektar Therapeutics (MM) Description
| Nektar Therapeutics, Inc, is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. |
